6 BlackRock Zenas BioPharma Trades
BlackRock's position in Zenas BioPharma is currently worth $37.5M. That's 0.00% of their equity portfolio (2583rd largest holding). The investor owns 4.56% of the outstanding Zenas BioPharma stock. The investor's estimated purchase price is $53.1M, resulting in a loss of 29%.
News about Zenas BioPharma, Inc. and BlackRock
Investors Urged to Contact Levi & Korsinsky for Information Before June 16, 2025 - Zenas BioPharma, Inc. (ZBIO)
NEW YORK, NY / ACCESS Newswire / June 16, 2025 / If you suffered a loss on your Zenas BioPharma, Inc. (NASDAQ:ZBIO) investment and want to learn about a pote...
ZBIO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
NEW YORK, June 16, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors ...
ZBIO LAWSUIT ALERT: Levi & Korsinsky Notifies Zenas BioPharma, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, June 16, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Zenas BioPharma, Inc. ("Zenas BioPharma, Inc." or the "Company") (NAS...
ZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)---- $ZBIO--ZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm.